Smell as a clinical-marker for functional limitations in multiple sclerosis: A pilot study.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 29 06 2020
revised: 08 09 2020
accepted: 11 09 2020
pubmed: 5 10 2020
medline: 15 5 2021
entrez: 4 10 2020
Statut: ppublish

Résumé

Olfactory dysfunction is a common symptom of multiple sclerosis (MS). The questions of whether and to what degree olfactory dysfunction can serve as a clinical marker of MS disability (i.e. cognitive impairments and functional limitations) are not yet answered. The current study aimed to explore associations between olfactory function (i.e. smell identification) with cognitive capacities, functional performance and quality of life (QOL) in persons with MS. Olfactory function was measured by the University of Pennsylvania Smell Identification Test (UPSIT). Functional ability was assessed by the Actual Reality MS patients had lower UPSIT scores than healthy controls. Worse UPSIT scores were associated with reduced performances on the BICAMS and AR task as well as lower MSQOL-54 scores. Specifically, UPSIT scores were related to MSQOL-54 scores independent of BICAMS composite scores, while the relationship between UPSIT score and AR performance was mediated by BICAMS composite score. This study confirms previous studies which concluded that olfactory function is impaired in MS. Furthermore, olfactory dysfunction is related to limitations in activity performance and QOL. Taken together with previous studies, olfactory function may be considered as a clinical marker related to MS disability. Longitudinal studies are needed to confirm these results.

Sections du résumé

BACKGROUND BACKGROUND
Olfactory dysfunction is a common symptom of multiple sclerosis (MS). The questions of whether and to what degree olfactory dysfunction can serve as a clinical marker of MS disability (i.e. cognitive impairments and functional limitations) are not yet answered. The current study aimed to explore associations between olfactory function (i.e. smell identification) with cognitive capacities, functional performance and quality of life (QOL) in persons with MS.
METHODS METHODS
Olfactory function was measured by the University of Pennsylvania Smell Identification Test (UPSIT). Functional ability was assessed by the Actual Reality
RESULTS RESULTS
MS patients had lower UPSIT scores than healthy controls. Worse UPSIT scores were associated with reduced performances on the BICAMS and AR task as well as lower MSQOL-54 scores. Specifically, UPSIT scores were related to MSQOL-54 scores independent of BICAMS composite scores, while the relationship between UPSIT score and AR performance was mediated by BICAMS composite score.
CONCLUSION CONCLUSIONS
This study confirms previous studies which concluded that olfactory function is impaired in MS. Furthermore, olfactory dysfunction is related to limitations in activity performance and QOL. Taken together with previous studies, olfactory function may be considered as a clinical marker related to MS disability. Longitudinal studies are needed to confirm these results.

Identifiants

pubmed: 33011622
pii: S2211-0348(20)30583-6
doi: 10.1016/j.msard.2020.102508
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102508

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Yael Goverover (Y)

Department of Occupational Therapy, Steinhardt School of Culture, Education, and Human Development, New York University, and Kessler Foundation, 82 Washington Square East, New York, NY, 10003, United States. Electronic address: yg243@nyu.edu.

Michelle H Chen (MH)

Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ 07936-3147.

Silvana L Costa (SL)

Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ 07936-3147.

Nancy D Chiaravalloti (ND)

Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ 07936-3147.

John DeLuca (J)

Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ 07936-3147.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH